Business Context and Reporting Period
This Form 8-K is a current report filed by NeuroBo Pharmaceuticals, Inc. (not Metavia Inc.) on February 9, 2023, regarding an event dated February 8, 2023. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "NRBO".
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The Company received a notice from Nasdaq stating it is not in compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) because its closing bid price remained below $1.00 for 30 consecutive trading days.
Guidance, Outlook, and Risks
- Compliance Period: The Company has 180 calendar days (until August 7, 2023) to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days.
- Extension Options: If compliance is not met by the deadline, the Company may be eligible for an additional 180-day period if it meets other listing standards (e.g., market value of publicly held shares) and intends to cure the deficiency, potentially via a reverse stock split.
- Delisting Risk: Failure to regain compliance within the allotted time, including any extensions, will result in a notice of delisting. The Company may appeal this determination to a Nasdaq hearings panel.
- Management Action: Management intends to actively monitor the stock price and consider available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current trading price of NRBO to assess proximity to the $1.00 threshold.
- Monitor future announcements regarding the Company's intent to execute a reverse stock split if the initial compliance period expires.
- Review the Company's market value of publicly held shares to determine eligibility for a second compliance period.
- Check for any subsequent 8-K filings confirming compliance or notice of delisting.